Compare GRDN & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | PRGO |
|---|---|---|
| Founded | 2004 | 1887 |
| Country | United States | Ireland |
| Employees | 3400 | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 2013 |
| Metric | GRDN | PRGO |
|---|---|---|
| Price | $33.37 | $9.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $33.33 | $19.33 |
| AVG Volume (30 Days) | 177.2K | ★ 3.2M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | ★ 11.82% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | $1.13 | N/A |
| Revenue Next Year | $9.97 | $1.02 |
| P/E Ratio | $117.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.17 | $9.70 |
| 52 Week High | $37.43 | $29.08 |
| Indicator | GRDN | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 16.79 |
| Support Level | $28.07 | N/A |
| Resistance Level | $34.98 | $14.84 |
| Average True Range (ATR) | 1.63 | 0.64 |
| MACD | -0.12 | -0.40 |
| Stochastic Oscillator | 46.46 | 2.97 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.